Using the newborn NOD/SCID/IL2rγ null xenotransplantation model, we demonstrate that CD34+CD38+CD19+ cells as well as CD34+CD38−CD19+ cells have the capacities to initiate B-ALL, to infiltrate into ...

Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: a single-institute study of 96 patients. The objective of ...

CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. Prevention of skin cancer and reduction of keratotic skin lesions during ...

Please provide your email address to receive an email when new articles are posted on . Doses of between 10 and 15 million CD34+ cells, when compared to lesser amounts, were shown in a study to ...

Baxter International Inc. (NYSE:BAX) announced today that it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous (an individual's own) CD34+ stem ...

Beauty-Stem Biomedical's Medical Seminar Unveils Remarkable Link Between CD34 Stem Cells and Human Well-Being: Regeneration, Immune Enhancement and Hematopoiesis LOS ANGELES, CA / ACCESSWIRE / July 28 ...

Differentiation of hair follicle stem cells (HFSCs) into neurons and glial cells represents a promising cell-based therapy for neurodegenerative diseases. The hair follicle bulge area is reported as a ...

A stroke therapy using stem cells extracted from patients’ bone marrow has shown promising results in the first trial of its kind in humans. The therapy uses a type of cell called CD34+ cells, a set ...

This study examined haematopoietic stem cells of 19 high-risk cases of myelodysplastic syndrome (MDS) for apoptotic and anti-apoptotic signals and cellular proliferation and correlated these with ...

Here, we describe the first two patients, one with TDT and the other with SCD, who were infused with CTX001 (autologous CRISPR-Cas9–edited CD34+ HSPCs that were genetically edited to reactivate the ...

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc. ( “Company”, or “EdiGene”), today announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has ...